Tonghua Dongbao Pharmaceutical's EPS and revenue saw a dip, ...
Tonghua Dongbao Pharmaceutical's EPS and revenue saw a dip, but share prices still rose, indicating that investors might be considering factors other than EPS. The annual shareholder return was 38%, primarily from dividends, significantly outperforming the 1.1% TSR loss over five years.
Tonghua Dongbao Pharmaceutical's (SHSE:600867) Investors Will Be Pleased With Their Respectable 38% Return Over the Last Year
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
4522Followers
0Following
9908Visitors
Follow